Trinity Biotech plans 1-for-30 reverse ADS split via ratio change
TRIB•ADS ratio change to create 1-for-30 reverse split
Trinity Biotech plans to change its ADS ratio to 1 ADS for 600 Class A ordinary shares from 1 ADS for 20.
The move equates to a 1-for-30 reverse ADS split, targeting Nasdaq’s $1 minimum bid rule.
The ratio change is expected to take effect at the open on July 24, 2026, with the ticker remaining TRIB.
No fractional new ADSs will be issued; fractional entitlements will be aggregated, sold, then paid out in cash net of costs.
